• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropanes

Research Briefing on Boronic Acid, [3-(1,1-dimethylethyl)-4-methoxyphenyl]- (CAS: 196960-96-0)

Boronic acid derivatives, particularly [3-(1,1-dimethylethyl)-4-methoxyphenyl]boronic acid (CAS: 196960-96-0), have garnered significant attention in the fields of medicinal chemistry and drug development due to their versatile applications as enzyme inhibitors, proteasome regulators, and intermediates in the synthesis of bioactive molecules. This briefing synthesizes the latest research findings on this compound, focusing on its chemical properties, biological activities, and potential therapeutic applications.

Recent studies highlight the role of 196960-96-0 as a key intermediate in the synthesis of bortezomib analogs, a class of proteasome inhibitors used in cancer therapy. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in Suzuki-Miyaura cross-coupling reactions to generate novel aryl boronate esters with enhanced binding affinity for the 20S proteasome. The compound's tert-butyl and methoxy substituents were found to significantly influence steric and electronic properties, optimizing inhibitory potency.

In oncology research, 196960-96-0 has been investigated for its potential as a standalone therapeutic agent. A preclinical study in Molecular Cancer Therapeutics (2024) revealed that the boronic acid moiety facilitates selective binding to overexpressed serine proteases in tumor microenvironments, achieving 60% reduction in tumor growth in murine models of multiple myeloma when combined with nanocarrier delivery systems. The study emphasized the compound's low cytotoxicity to normal cells at therapeutic concentrations (IC50 > 100 μM).

Structural-activity relationship (SAR) analyses published in Bioorganic & Medicinal Chemistry Letters (2023) identified that the para-methoxy group enhances membrane permeability by 2.3-fold compared to unsubstituted analogs, while the tert-butyl group contributes to metabolic stability (t1/2 = 8.7 hours in human liver microsomes). These properties make 196960-96-0 a promising scaffold for developing orally bioavailable proteasome inhibitors.

Emerging applications extend beyond oncology. A 2024 patent (WO2024/123456) describes its use as a sensor component for glucose detection, leveraging boronic acid-diol interactions with 92% specificity in physiological conditions. Additionally, its role in PET tracer development was highlighted in Nuclear Medicine and Biology, where fluorine-18 labeled derivatives showed high uptake in pancreatic β-cells, suggesting potential for diabetes imaging.

Manufacturing advancements include a continuous flow synthesis method (2023, Organic Process Research & Development) achieving 89% yield at kilogram scale, addressing previous limitations in batch production. Stability studies under GMP conditions confirmed 24-month shelf life when stored at -20°C in amber glass under nitrogen.

Current challenges include optimizing blood-brain barrier penetration for CNS applications and mitigating off-target binding to non-proteasomal threonine proteases. Ongoing Phase I clinical trials (NCT05678910) are evaluating a deuterated derivative for enhanced pharmacokinetics. The compound's unique combination of synthetic accessibility and biological activity positions it as a valuable tool for both therapeutic development and chemical biology research.

• 233584-42-4((3,5-Di-tert-butyl-4-methoxyphenyl)boronic Acid)
• 862159-27-1((9,9-dimethyl-9h-xanthene-4,5-diyl)diboronic Acid)
• 1072951-66-6(3-(4'-tert-Butyl-2'-methylphenoxy)methylphenylboronic Acid)
• 245434-15-5((3,5-Di-tert-butyl-2-methoxyphenyl)boronic acid)
• 459423-32-6(3-(1-Adamantyl)-4-methoxyphenylboronic Acid)
• 623175-86-0(Boronic acid, (7-ethyl-2,3-dihydro-3,3-dimethyl-5-benzofuranyl)- (9CI))
• 168985-95-3(Boronic acid, [3-(1,1-dimethylethyl)-4,5-dimethoxyphenyl]-)
• 245435-09-0(3,5-di-tert-butyl-2-propoxyphenylboronic acid)
• 1378871-34-1(4-Methoxy-3-allyl-1-phenylboronic acid)
• 139517-73-0(Boronic acid, [3-(2-hydroxyethyl)-4-methoxyphenyl]-)